Veraxa Biotech is trading 7.69% down now at $1.80, amid broad weakness in biotechnology shares.
- On August 24, 2026, Veraxa Biotech and Secarna Pharmaceuticals announced positive early research results.
- Their antibody-oligonucleotide conjugate candidate showed greater potency than an unconjugated oligonucleotide.
- No credible negative company-specific catalyst was identified; the Nasdaq Biotechnology index was down 0.71%.